Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for cardiac amyloidosis, a ...

OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...

In a new study published in the European Heart Journal, researchers reported the successful development and validation of a medical artificial intelligence (AI) model that screens for cardiac ...

The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...

"These forms of cardiac amyloidosis are rare but increasingly recognized. For the first time, patients with both forms of amyloidosis have undergone deep phenotyping using cardiac biomarkers, 12-lead ...

Serum and urine immunofixation and serum free light chain assay is recommended to increase clinical suspicion of cardiac AL amyloidosis for individuals with suspected cardiac amyloidosis. HealthDay ...

Share on Pinterest A study of bone scans is helping scientists determine the prevalence of cardiac amyloidosis. Ben Hasty/MediaNews Group/Reading Eagle via Getty Images Cardiac amyloidosis (CA) causes ...